Reuters logo
BRIEF-FDA accepts Otsuka's resubmission to support a regulatory review of Tolvaptan in the treatment of ADPKD
2017年11月9日 / 下午12点32分 / 12 天前

BRIEF-FDA accepts Otsuka's resubmission to support a regulatory review of Tolvaptan in the treatment of ADPKD

Nov 9 (Reuters) - Otsuka Holdings Co Ltd

* FDA accepts Otsuka’s resubmission to support a regulatory review of Tolvaptan in the treatment of ADPKD

* ‍otsuka Pharmaceutical - FDA accepts Otsuka’s resubmission to support a regulatory review of tolvaptan in treatment of adpkd​

* Otsuka Holdings Co Ltd - ‍April 2018 is anticipated completion timing of FDA’s review based on PDUFA timeline ​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below